Nitric oxide-dependent endothelial function and cardiovascular disease

被引:87
作者
Desjardins, F. [1 ]
Balligand, J. -L. [1 ]
机构
[1] Catholic Univ Louvain, Unit Pharmacol & Therapeut, Dept Med, B-1200 Brussels, Belgium
关键词
nitric oxide; endothetial dysfunction; cardiovascular disease;
D O I
10.1179/acb.2006.052
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nitric oxide produced by three different isoforms of nitric oxide synthase (NOS) widely expressed in virtually all vascular cell types is mostly produced by the endothelial isoform (eNOS) in endothelial cells where it plays a crucial role in vascular tone and structure regulation. It also exerts an anti-inflammatory influence, inhibits platelets adhesion and aggregation, and prevents smooth muscle cells proliferation and migration. Several lines of evidence link endothelial dysfunction, characterized by decreased bioavailability of nitric oxide, with the development of many pathological conditions such as heart failure, hypertension, diabetes and atherosclerosis. This review focuses on nitric oxide-dependent endothelial dysfunction in cardiovascular diseases, its clinical detection and relevance, potential pathogenic mechanisms and possible therapies.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 38 条
[1]   Stoichiometric relationships between endothelial tetrahydrobiopterin, endothelial NO synthase (eNOS) activity, and eNOS coupling in vivo - Insights from transgenic mice with endothelial-targeted GTP cyclohydrolase 1 and eNOS overexpression [J].
Bendall, JK ;
Alp, NJ ;
Warrick, N ;
Cai, SJ ;
Adlam, D ;
Rockett, K ;
Yokoyama, M ;
Kawashima, S ;
Channon, KM .
CIRCULATION RESEARCH, 2005, 97 (09) :864-871
[2]   Asymmetric dimethylarginine (ADMA):: A novel risk marker in cardiovascular medicine and beyond [J].
Böger, RH .
ANNALS OF MEDICINE, 2006, 38 (02) :126-136
[3]   Regulation of endothelium-derived vasoactive autacoid production by hemodynamic forces [J].
Busse, R ;
Fleming, I .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (01) :24-29
[4]   Metabolic syndrome-interdependence and metabolic pathways [J].
Caglayan, E ;
Blaschke, F ;
Takata, Y ;
Hsueh, WA .
CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (02) :135-142
[5]   Peroxisome proliferator-activated receptor-γ activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors [J].
Campia, U ;
Matuskey, LA ;
Panza, JA .
CIRCULATION, 2006, 113 (06) :867-875
[6]   Intensive versus moderate lipid lowering with statins after acute coronary syndromes [J].
Cannon, CP ;
Braunwald, E ;
McCabe, CH ;
Rader, DJ ;
Rouleau, JL ;
Belder, R ;
Joyal, SV ;
Hill, KA ;
Pfeffer, MA ;
Skene, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1495-1504
[7]   Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis - Genetic and physiological evidence [J].
Dayoub, H ;
Achan, V ;
Adimoolam, S ;
Jacobi, J ;
Stuehlinger, MC ;
Wang, BY ;
Tsao, PS ;
Kimoto, M ;
Vallance, P ;
Patterson, AJ ;
Cooke, JP .
CIRCULATION, 2003, 108 (24) :3042-3047
[8]   Endothelial dysfunction:: a multifaceted disorder [J].
Feletou, Michel ;
Vanhoutte, Paul M. .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 291 (03) :H985-H1002
[9]   Caveolins and the regulation of endothelial nitric oxide synthase in the heart [J].
Feron, O ;
Balligand, JL .
CARDIOVASCULAR RESEARCH, 2006, 69 (04) :788-797
[10]  
Feron O, 2001, CIRCULATION, V103, P113